BRCA is the most common cancer in women. The 2018 GLOBOCAN report disclosed that approximately 2.1 million women worldwide were diagnosed with BRCA in 2018, accounting for one-fourth of all cancer cases among women. 1 According to clinicopathological criteria, BRCA is divided into four subtypes Luminal A, Luminal B, Erb-B2 overexpression, and Basal-like, represents a convenient approximation. 2 Ihemelandu study indicated that Luminal A type accounts for 50% of BRCA patients, Luminal B, Erb-B2 overexpression, and Basal-like subtypes accounted for 14.1%, 12.7%, and 23.2%, respectively. 3 For ER receptor-positive BRCA, tamoxifen, and aromatase inhibitors are effective endocrine therapies. 4 For HER2-positive BRCA, the monoclonal antibody trastuzumab and lapatinib have been approved as the most specific molecular targeting drugs. 5,6 With the development of medical technology, the prognosis of BRCA has been